bump & a reg med ping
This is no small thing. Recently I had to have surgery for an eye problem believed to be related to this problem. Fortunately it was corrected but many people have to undergo regular shots for this problem which is the breaking of small blood vessels in the eye that cloud the vision. Those shots cost the small sum of $2,000 a pop.
If anyone with diabetes or pre-diabetes doesn’t take this problem serious, wait until you have to get a white cane and are house bound.
Developing a complicated procedure to purify stem cells for human trials was difficult at Scripps, because academic settings and government grants support basic research, not the applied-process development required for such targeted research, and Friedlander didn't want to go the typical venture-capital route. So instead, he approached Pfizer (nyse: PFE - news - people ) about funding a company to commercialize the therapy. His timing was good, as Pfizer this April started a new regenerative-medicine unit devoted to therapies involving stem cells. "Pfizer has put its flag in the ground that there is future in regenerative medicine," said Corey Goodman, president of the company's biotech unit. "The eye is a very good place to be starting--it is an isolated organ, and there is a huge need."
The drug maker is putting in a modest $3 million to get the new company of the ground. But if the therapy looks promising in a couple of years, Pfizer has the right of first refusal to buy it outright. The concept is to combine "the entrepreneurial spirit of the start-up, but with the muscle and clout and access to resources of a pharmaceutical company," said Goodman. It's far from being a passive investment; Goodman says Pfizer's top scientists will work with Friedlander and his team. Goodman also says Pfizer would consider more deals like this in the future. The company has little to lose by trying new things. Its stock is in the dumps, and its main drug, Lipitor, will face patent expiration in 2011.
Few good treatments exist for diabetic retinopathy, in which blood vessels that bring oxygen to the retina grow abnormally, leading to leakage of fluid or blood cells. To solve the problem, doctors sometimes resort to the radical step of using lasers to kill retina cells responsible for peripheral vision in order to preserve enough oxygen for those engaged in central vision. Far better would be a treatment that repaired the vessel damage and restored proper blood flow. The first focus for EyeCyte will devise an efficient procedure for isolating and purifying the stem cells, called "CD44 high." Purified stem cells would be injected into a patient's eyes, where they would mature into support cells that could jump-start healing.
The object is to have a stem-cell treatment ready for human trials within three years, said Mohammad A. El-Kalay, EyeCyte chief executive and a veteran of several cell-therapy companies. When he heard about the technology four years ago, he "got very excited" because it looked like there might be enough cells in one patient's blood to treat the eyes without having to laboriously grow more cells in the lab. "The goal is to intervene with these progenitor cells, stabilize the eye and prevent things from getting worse," said Friedlander. If it works as well as he hopes, one stem-cell injection might prevent further damage for as long as a decade. Friedlander's stem-cell therapy could one day compete with drugs like Lucentis from Genentech (nyse: DNA - news - people ). This drug is approved for macular degeneration and is in testing for diabetic eye disease. Novartis (nyse: NVS - news - people ) also sells treatments for various eye diseases. Besides Pfizer, one of the few big drug companies involved in cell therapy is Johnson & Johnson (nyse: JNJ - news - people ). It is an investor in the San Diego biotech company Novocell, which is developing stem-cell therapy to cure diabetes.